Nasdaq · Healthcare
AMGEN INC (AMGN)
As-reported financials and recent SEC filings for AMGEN INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$36.75B
Net income
$7.71B
Net margin
21.0%
Diluted EPS
$14.23
ROE
89.1%
P/E (TTM)
24.7×
Market cap
$191.70B
Debt / equity
5.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B |
| Gross profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.52B |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| Diluted EPS | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →Go deeper on AMGN
Search AMGEN INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.